Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides

Summary

This phase II trial studies how well pembrolizumab works in treating patients with stage IB-IV mycosis fungoides. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Timeline

Start

2020-02-04

Primary completion

2023-06-21

Completion

2024-10-08

Drugs

Indications